Leukapheresis Procedure at Chughtai Lab

Leukapheresis Procedure at Chughtai Lab

Leukapheresis is a highly specialized, advanced therapeutic and diagnostic apheresis procedure designed to selectively separate and remove white blood cells (leukocytes) from a patient’s blood. At Chughtai Lab, a premier diagnostic and healthcare network in Pakistan, this procedure is performed under stringent clinical protocols, utilizing state-of-the-art automated blood cell separators. The process involves drawing whole blood from the patient, passing it through an extracorporeal circuit where centrifugation separates the cellular components based on their density, isolating the target leukocyte fraction, and safely returning the remaining red blood cells, platelets, and plasma back into the patient’s circulation.

This procedure serves two primary clinical purposes: therapeutic cytoreduction and cellular harvesting. Therapeutically, leukapheresis is an emergency intervention used to rapidly reduce extremely elevated white blood cell counts (hyperleukocytosis) in patients suffering from acute leukemia, thereby preventing or treating life-threatening leukostasis. Diagnostically and preparatively, it is utilized to harvest peripheral blood stem cells (PBSCs) or mononuclear cells for autologous or allogeneic stem cell transplantation, as well as for advanced cellular immunotherapies. By leveraging cutting-edge continuous-flow centrifugation technology, Chughtai Lab ensures optimal extraction efficiency while prioritizing patient safety, hemodynamic stability, and comfort throughout this complex hematological intervention.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is critical to ensure patient safety, optimize leukocyte yield, and minimize the risk of procedural complications. Patients undergoing leukapheresis at Chughtai Lab are advised to adhere to the following guidelines:

• Comprehensive Medical Evaluation: Prior to the procedure, a consultant hematologist conducts a thorough clinical assessment, reviewing the patient’s medical history, current medications, and indications for apheresis.
• Baseline Laboratory Testing: A complete blood count (CBC), coagulation profile (PT/APTT), and serum electrolyte panel (specifically focusing on ionized calcium, potassium, and magnesium) must be performed within 24 hours of the procedure.
• Vascular Access Assessment: The clinical team evaluates the patient’s peripheral veins for adequacy. If peripheral access is insufficient to support the high flow rates required for apheresis, the placement of a temporary double-lumen central venous catheter (apheresis catheter) is arranged.
• Hydration and Nutrition: Patients are encouraged to consume plenty of oral fluids (water and clear juices) for 24 to 48 hours prior to the session to maintain intravascular volume. A light, non-fatty meal should be eaten on the morning of the procedure.
• Calcium-Rich Diet: Because the anticoagulant used during apheresis (acid citrate dextrose) binds to ionized calcium in the bloodstream, patients are advised to eat calcium-rich foods or take prescribed oral calcium supplements before the procedure to mitigate the risk of hypocalcemia.
• Medication Review: Patients must inform the clinical team of all medications they are taking. Certain drugs, particularly anticoagulants or antiplatelet agents, may need to be temporarily adjusted or held under medical supervision.

During the Procedure

The leukapheresis procedure is conducted in a specialized, sterile apheresis suite at Chughtai Lab, closely monitored by experienced transfusion medicine specialists and nursing staff. The process unfolds through the following structured phases:

• Patient Positioning and Monitoring: The patient is comfortably positioned in a specialized reclining apheresis chair or bed. Continuous monitoring of vital signs, including blood pressure, heart rate, respiratory rate, and oxygen saturation, is established and maintained throughout the session.
• Establishing Vascular Access: Two venipuncture sites are prepared. One site (the draw line) is used to extract blood, and the second site (the return line) is used to reinfuse the processed blood. If a central venous catheter is present, it is sterilely accessed and connected to the apheresis machine.
• Extracorporeal Circulation and Separation: Whole blood is drawn into the automated cell separator. Inside the machine’s sterile, single-use disposable kit, the blood is mixed with an anticoagulant (Citrate Dextrose Solution, Formula A) to prevent clotting. The blood is then centrifuged, separating it into distinct layers: red blood cells, the buffy coat (containing white blood cells and platelets), and plasma.
• Targeted Leukocyte Extraction: The machine’s optical sensors precisely identify and divert the leukocyte-rich buffy coat into a collection bag, while the remaining blood components are immediately recombined and returned to the patient.
• Mitigating Citrate Toxicity: To counteract the calcium-binding effects of the citrate anticoagulant, a continuous intravenous infusion of calcium gluconate may be administered, or oral calcium tablets may be provided during the procedure. Staff closely monitor the patient for early signs of hypocalcemia, such as perioral tingling, muscle cramps, or chills.
• Duration and Completion: A typical leukapheresis session lasts between 2 to 4 hours, depending on the patient’s total blood volume, baseline white blood cell count, and the specific therapeutic or harvesting goals. Once the target processing volume is achieved, the lines are flushed, vascular access is discontinued, and sterile dressings are applied.

When is a Leukapheresis Procedure Performed?

Hyperleukocytosis and Leukostasis Management

Physicians request emergency therapeutic leukapheresis when a patient presents with hyperleukocytosis, typically defined as a white blood cell count exceeding 100,000/µL. This extreme elevation of leukocytes, most commonly seen in acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), significantly increases blood viscosity. This leads to leukostasis, a medical emergency characterized by microvascular sludging, tissue hypoxia, and organ dysfunction. Leukapheresis is performed rapidly to lower the circulating blast count, relieving microvascular congestion and preventing catastrophic complications such as pulmonary failure or intracranial hemorrhage.

Acute Myeloid Leukemia (AML) Cytoreduction

In patients newly diagnosed with Acute Myeloid Leukemia (AML) who present with extremely high blast counts, leukapheresis is utilized as an adjunctive cytoreductive therapy. While definitive treatment requires systemic chemotherapy, chemotherapy-induced cell lysis can trigger severe tumor lysis syndrome (TLS). Performing leukapheresis prior to initiating chemotherapy safely reduces the tumor burden, minimizes the risk of TLS, stabilizes the patient’s hemodynamic status, and allows the primary oncology team to initiate definitive treatment with a significantly lower risk of metabolic and renal complications.

Chronic Leukemia Cytoreduction

Patients with Chronic Myelogenous Leukemia (CML) or Chronic Lymphocytic Leukemia (CLL) may occasionally develop symptomatic, extreme leukocytosis that does not respond immediately to oral cytoreductive agents like hydroxyurea. In these clinical scenarios, leukapheresis is performed to achieve rapid, controlled reduction of the white blood cell mass. This intervention helps alleviate symptoms such as severe splenomegaly, abdominal discomfort, fatigue, and constitutional symptoms, stabilizing the patient until long-term targeted therapies or chemotherapeutic regimens take effect.

Peripheral Blood Stem Cell (PBSC) Harvesting

Leukapheresis is the standard method for collecting hematopoietic stem cells from the peripheral blood for patients undergoing autologous or allogeneic stem cell transplantation. Prior to collection, the donor or patient receives mobilizing agents (such as granulocyte colony-stimulating factor, or G-CSF) to stimulate the bone marrow to release stem cells into the bloodstream. Leukapheresis is then performed to harvest these circulating CD34+ stem cells, which are subsequently processed, cryopreserved, and eventually reinfused to reconstitute the patient’s bone marrow following high-dose chemotherapy.

Mononuclear Cell Collection for Immunotherapy

With the advent of advanced cellular immunotherapies, including Chimeric Antigen Receptor T-cell (CAR-T) therapy and dendritic cell vaccines, leukapheresis has become a foundational procedure for harvesting healthy mononuclear cells. Physicians order this specialized collection to obtain a high-quality yield of T-lymphocytes from the patient. These harvested cells are sent to specialized laboratory facilities where they are genetically engineered to target specific cancer proteins before being expanded and reinfused into the patient to fight malignancies.

What Does a Leukapheresis Procedure Achieve?

The leukapheresis procedure at Chughtai Lab is designed to monitor, manage, and achieve several critical clinical parameters and therapeutic outcomes, including:

• Rapid Reduction of Total White Blood Cell (WBC) Count: Achieving a significant, controlled decrease in circulating leukocytes to safe clinical thresholds.
• Alleviation of Leukostasis Symptoms: Reversing clinical signs of microvascular sludging, such as dyspnea, hypoxia, headache, visual disturbances, and confusion.
• Targeted Extraction of Mononuclear Cells: Isolating high-purity lymphocytes and monocytes for therapeutic or diagnostic applications.
• High-Yield CD34+ Stem Cell Collection: Harvesting an optimal quantity of hematopoietic stem cells required for successful bone marrow engraftment.
• Prevention of Intracranial Hemorrhage: Reducing the risk of cerebral vascular occlusion and subsequent hemorrhage in acute leukemia patients.
• Mitigation of Pulmonary Insufficiency: Clearing leukostatic aggregates from the pulmonary microvasculature to improve oxygenation and gas exchange.
• Prevention of Tumor Lysis Syndrome (TLS): Lowering the systemic tumor burden mechanically to prevent severe metabolic derangements during chemotherapy.
• Preservation of Red Blood Cell Mass: Ensuring minimal loss of erythrocytes during the continuous separation process.
• Preservation of Platelet Levels: Minimizing unintended platelet depletion, especially in patients who are already thrombocytopenic.
• Maintenance of Hemodynamic Stability: Ensuring stable blood pressure and cardiac output by balancing extracorporeal volume with continuous return.
• Safe Anticoagulation Management: Achieving optimal anticoagulation within the apheresis circuit without inducing systemic bleeding.
• Prevention of Citrate-Induced Hypocalcemia: Carefully managing calcium levels through proactive monitoring and supplementation.
• Reduction of Splenomegaly-Related Discomfort: Decreasing the physical size of the spleen by reducing the systemic leukocyte burden.
• Collection of Granulocytes: Harvesting functional neutrophils for transfusion into severely neutropenic patients with refractory infections.
• Optimization of Extracorporeal Blood Flow: Managing inlet and outlet flow rates to maximize separation efficiency while protecting venous integrity.
• Reduction of Blood Viscosity: Mechanically lowering whole blood viscosity to restore normal microcirculatory perfusion.
• Safe Processing of Total Blood Volume: Successfully processing 2 to 3 times the patient’s total blood volume in a single session.
• Minimization of Procedural Blood Loss: Ensuring the sterile, complete return of non-targeted blood components.
• Post-Procedure Hematocrit Stabilization: Maintaining stable red cell indices post-apheresis.
• Post-Procedure Platelet Stabilization: Ensuring post-procedure platelet counts remain within clinically safe margins.
• Successful Cryopreservation of Harvested Cells: Ensuring the viability of collected stem cells or mononuclear cells for future therapeutic use.

Turnaround Time and Report Access at Chughtai Lab

At Chughtai Lab, the reporting and monitoring process for a leukapheresis procedure is immediate and highly integrated. Because leukapheresis is an active clinical intervention, real-time laboratory monitoring is essential. Complete Blood Counts (CBC) are performed immediately before, during (if required for long procedures), and immediately after the session to quantify the exact reduction in white blood cells and to assess post-procedure platelet and hematocrit levels. These rapid-turnaround laboratory results are typically available within an hour of sample collection, allowing the attending hematologist to make immediate clinical decisions regarding the need for subsequent apheresis sessions.

For stem cell harvesting or mononuclear cell collections, specialized flow cytometry reports detailing the exact CD34+ cell count or mononuclear cell yield are processed with high priority. Chughtai Lab provides seamless digital access to all pre- and post-procedure laboratory reports. Patients and referring physicians can securely access, download, and share these reports through the Chughtai Lab mobile application or the official online web portal, ensuring rapid, integrated, and coordinated clinical care.

Leukapheresis Findings Overview

The following table outlines the key clinical parameters evaluated before, during, and after a leukapheresis procedure, along with their normal and abnormal clinical implications:

Parameter Evaluated	Normal / Target Findings	Possible Abnormal Findings
Total White Blood Cell (WBC) Count	Significant reduction post-procedure (typically >30% to 60% decrease from baseline).	Persistent, refractory hyperleukocytosis; inadequate cytoreduction requiring repeat sessions.
CD34+ Stem Cell Yield (Harvesting)	Target yield achieved (typically ≥ 2 x 10^6 CD34+ cells/kg of patient weight).	Suboptimal stem cell yield; poor mobilization requiring additional collection days or alternative mobilization strategies.
Serum Ionized Calcium	Maintained within normal physiological limits (1.15–1.33 mmol/L) with proactive supplementation.	Hypocalcemia (ionized calcium < 1.10 mmol/L) presenting with paresthesia, muscle spasms, or cardiac arrhythmias.
Platelet Count	Post-procedure platelet count maintained within safe limits (>50,000/µL or stable relative to baseline).	Severe post-apheresis thrombocytopenia due to unintended platelet consumption within the circuit.
Hematocrit / Hemoglobin	Stable post-procedure values, indicating minimal red blood cell loss during the cycle.	Significant drop in hemoglobin/hematocrit, indicating hemolysis or excessive red cell retention in the kit.
Clinical Signs of Leukostasis	Complete resolution or significant improvement in neurological, visual, and respiratory symptoms.	Persistent or worsening dyspnea, altered mental status, or focal neurological deficits indicating ongoing tissue hypoxia.
Vascular Access Patency	Continuous, unobstructed blood flow (typically 50–100 mL/min) without high venous pressure alarms.	Inadequate flow rates, frequent machine alarms, hematoma formation, or catheter thrombosis.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for Leukapheresis?

• Experienced Healthcare Professionals: The procedure is performed and supervised by highly qualified consultant hematologists, transfusion medicine specialists, and certified apheresis nurses.
• Patient-Focused Care: Every patient receives individualized attention, with continuous clinical monitoring and supportive care in a dedicated, comfortable environment.
• Quality Diagnostic Services: Chughtai Lab integrates advanced laboratory diagnostics to provide rapid, highly accurate pre- and post-procedure blood counts and flow cytometry.
• Professional Reporting: Detailed procedural logs and laboratory results are generated promptly, ensuring referring oncologists have precise data for ongoing treatment planning.
• Modern Diagnostic Approach: Utilizing state-of-the-art, automated continuous-flow cell separators that maximize extraction efficiency while minimizing extracorporeal volume.
• Comfortable Environment: The specialized apheresis suites are designed to provide a calm, sterile, and relaxing atmosphere for patients during their multi-hour procedures.
• Convenient Location: With an extensive network of diagnostic centers and hospital-linked facilities across Pakistan, Chughtai Lab offers accessible, high-tier clinical services.
• Commitment to Accurate Diagnosis and Therapy: Adhering to international standards of transfusion medicine and apheresis safety, ensuring the highest level of clinical excellence and patient safety.